Amniotics AB (publ) today announced it has been invited to finalise a grant agreement with the European Innovation Council (EIC) as part of a consortium set to receive a grant of €3,8 Million from the EIC Pathfinder programme. This grant will fund the development of iPS derived, enhanced Natural Killer (NK) cells by a consortium led by Amniotics AB. Other participants are Lund University, Medizinische Hochschule Hannover and the University of Copenhagen.
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that the first patient hasnbeen dosed in its Phase Ib clinical study evaluating the lung-specific stem cell therapynPulmoStem™ in hospitalized patients with severe respiratory infections, including COVID-19,nInfluenza A, and other causes.
Drugmakers Hunt for One Vaccine to Target All Covid Variants
Amniotics granted key U.S. patent for PulmoStem